Oculis Holding AG (OCS)
| Market Cap | 953.83M |
| Revenue (ttm) | 1.03M |
| Net Income (ttm) | -82.42M |
| Shares Out | 41.94M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,062 |
| Open | 22.19 |
| Previous Close | 22.21 |
| Day's Range | 22.19 - 22.74 |
| 52-Week Range | 10.55 - 23.08 |
| Beta | -0.05 |
| Analysts | Strong Buy |
| Price Target | 28.80 (+26.65%) |
| Earnings Date | Mar 17, 2025 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneratio... [Read more]
Financial Performance
In 2023, Oculis Holding AG's revenue was 883,000, a decrease of -3.18% compared to the previous year's 912,000. Losses were -88.80 million, 129.5% more than in 2022.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price forecast is $28.8, which is an increase of 26.65% from the latest price.
News
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Cla...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Co...
Oculis to Present at the Stifel 2024 Healthcare Conference
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune r...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collabora...
Oculis to Present at Upcoming September Investor Conferences
ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis Publishes Consolidated Q2 Financial Statements and MD&A
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with...
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...
Oculis Reports Q2 Financial Results and Provides Recent Company Update
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and i...
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis and EURETINA Announces the Ramin Tadayoni Award
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and impr...
Oculis updates share capital for its existing at-the-market offering program
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, ...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and impr...
Oculis Publishes Invitation to the Annual General Meeting
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 M...
Oculis to Present at Bank of America Global Healthcare Conference
ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to sav...
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
ZUG, Switzerland, April 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”) today announced that it closed its registered direct offering, successful...
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
ZUG, Switzerland, April 11, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”), today announced that on April 11, 2024 it completed a financing of appro...